Quick Answer
Viridian Therapeutics, Inc.DE reported Operating Income Loss of -$363.40 million for the year ending 2025.
- Viridian Therapeutics, Inc.DE showed a decrease of -21.5% in Operating Income Loss from 2024 to 2025.
- This data is from Viridian Therapeutics, Inc.DE's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$60.4 thousand | Q3 2013: -$311.7 thousand | Q1 2014: -$167.0 thousand | Q2 2014: -$2.81 million | Q3 2014: -$1.63 million | Q1 2015: -$2.61 million | Q2 2015: -$2.49 million | Q3 2015: -$3.13 million | Q1 2016: -$3.54 million | Q2 2016: -$3.45 million | Q3 2016: -$4.08 million | Q1 2017: -$6.94 million | Q2 2017: -$7.35 million | Q3 2017: -$5.89 million | Q1 2018: -$4.62 million | Q2 2018: -$8.86 million | Q3 2018: -$9.15 million | Q1 2019: -$11.74 million | Q2 2019: -$8.94 million | Q3 2019: -$11.23 million | Q1 2020: -$8.00 million | Q2 2020: -$6.37 million | Q3 2020: -$5.41 million | Q1 2021: -$18.52 million | Q2 2021: -$18.00 million | Q3 2021: -$14.13 million | Q1 2022: -$25.89 million | Q2 2022: -$29.56 million | Q3 2022: -$29.79 million | Q1 2023: -$72.47 million | Q2 2023: -$59.28 million | Q3 2023: -$51.22 million | Q1 2024: -$55.90 million | Q2 2024: -$72.19 million | Q3 2024: -$83.48 million | Q1 2025: -$93.87 million | Q2 2025: -$106.77 million | Q3 2025: -$40.01 million.
- Over the full 13 years of available data (2013 to 2025), Viridian Therapeutics, Inc.DE's Operating Income Loss has declined by 184,364.5%.
- Historical annual values: Fiscal year 2025: -$363.40 million | Fiscal year 2024: -$299.04 million | Fiscal year 2023: -$254.45 million | Fiscal year 2022: -$134.30 million | Fiscal year 2021: -$79.73 million | Fiscal year 2020: -$110.38 million | Fiscal year 2019: -$41.98 million | Fiscal year 2018: -$33.08 million | Fiscal year 2017: -$26.53 million | Fiscal year 2016: -$16.99 million | Fiscal year 2015: -$11.19 million | Fiscal year 2014: -$6.87 million | Fiscal year 2013: -$197.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: